Stevanato Group S.p.A. reports developments in drug containment, drug delivery and diagnostic solutions for pharmaceutical, biotechnology and life sciences customers. The company’s updates center on financial results, revenue mix from high-value solutions, guidance, margin trends and demand across its Biopharmaceutical and Diagnostic Solutions and Engineering segments.
Recurring announcements also cover manufacturing capacity, customer demand for advanced containment and delivery products, investor conference participation and management commentary on operating performance. Its news flow connects healthcare packaging and delivery technologies with the commercial and clinical needs of drug developers, diagnostics companies and life sciences customers.
Stevanato Group (NYSE: STVN) reported third-quarter 2026 revenue of €326.1 million, up 8% from the same period last year. Organic revenue also rose 8%. Net profit increased 16% to €41.8 million, and diluted earnings per share rose 15% to €0.15. Adjusted EBITDA increased 14% to €88.8 million, with its margin reaching 27.2%.
Biopharmaceutical and Diagnostic Solutions revenue rose 10% to €294.0 million, while Engineering revenue fell 12% to €32.0 million. Gross margin declined 10 basis points to 29.1%. Free cash flow was €21.7 million, and net debt was €353.7 million at September 30.
The company maintained its 2026 outlook: revenue of €1.260 billion–€1.280 billion, adjusted EBITDA of €335.0 million–€345.2 million and adjusted diluted EPS of €0.60–€0.62. It expects lower GLP-1 volumes and revenue than previously anticipated to moderate 2027 growth, but still expects low-single-digit growth next year.
Stevanato Group (NYSE: STVN) announced a collaboration with Aptar Pharma to support earlier evaluation of pre-filled syringe systems for injectable therapies. Joint testing combines Stevanato Group’s glass syringes with Aptar Pharma’s closure components. The companies aim to help drug developers assess packaging options earlier; data packages and regulatory support services are available.
Stevanato Group (STVN) will report its third-quarter 2026 financial results on November 3, 2026, at 6:30 a.m. EDT.
A conference call and webcast will follow at 8:30 a.m. EDT. Management’s presentation will be available that morning on the company’s Investor Relations website, where the webcast will be archived for three months.
Stevanato Group (STVN) will participate in two investor conferences in September 2026. The company is scheduled for the Morgan Stanley Annual Global Healthcare Conference in New York on Tuesday, September 15 at 1:50 p.m. ET, and the BofA Global Healthcare Conference in London on Tuesday, September 22 from 8:25 to 9:05 a.m. GMT.
Live webcasts of both events will be available in the Investors section of the company’s website, with replays accessible for approximately 90 days after each conference.
Stevanato Group (NYSE: STVN) reported second-quarter fiscal 2026 revenue of €302.0 million, up 8% year-over-year, with high-value solutions up 16% to €135.9 million and representing 45% of total revenue. Gross margin expanded 60 bps to 28.7%, while adjusted EBITDA rose 21% to €78.7 million, lifting adjusted EBITDA margin 280 bps to 26.0%.
The company completed the divestiture of its California-based subsidiary Balda C. Brewer, recording €12.2 million of one-time sale and transaction expenses, which reduced operating margin by 190 bps to 12.9% and net profit to €23.0 million (diluted EPS €0.08). Adjusted net profit grew 20% to €37.6 million and adjusted diluted EPS to €0.14.
BDS segment revenue increased 9% to €266.2 million, while Engineering segment revenue declined 2% to €35.8 million but improved gross margin to 12.0%. Stevanato updated full-year 2026 guidance, now expecting revenue of €1.260–€1.280 billion, adjusted EBITDA of €335.0–€345.2 million, and narrowed adjusted diluted EPS guidance to €0.60–€0.62.
Stevanato Group (NYSE: STVN) announced that liraglutide-based combination products incorporating its proprietary Alina® pen injector platform have received marketing authorizations in multiple European countries. The approvals relate to finished products held by the respective Marketing Authorization Holders and cover therapies for diabetes and weight management.
The authorized configurations include Alina® 30 for diabetes and Alina® 50 for weight management, both part of Stevanato Group’s variable-dose pen platform for GLP-1s and other injectables. According to Stevanato Group, Alina® is designed for scalable manufacturing and integration into existing pharmaceutical fill-finish and assembly supply chains.
Stevanato Group (NYSE: STVN) will release its second quarter 2026 financial results on Tuesday, August 4, 2026, at 6:30 a.m. EDT. Management will host a conference call and live listen-only webcast at 8:30 a.m. EDT the same day, supported by an online slide presentation.
Investors can pre-register to receive a conference passcode and unique PIN, or join via regional dial-in numbers in Italy, the United Kingdom, and the United States (including a U.S. toll-free option). A webcast replay will be available for three months on the company’s Investor Relations website.
Stevanato Group (NYSE: STVN) introduced Deora™, a proprietary, multi-use, fixed-dose pen injector for subcutaneous delivery in therapies such as diabetes and weight management, including incretin-based treatments.
Deora features an intuitive pull-push mechanism, supports fixed-dose volumes up to 0.75 mL, works with standard 1.5 mL and 3 mL cartridges, and is designed for scalable manufacturing and integration into existing pharmaceutical supply chains.
Stevanato Group (NYSE: STVN) announced that all resolutions at its May 26, 2026 Ordinary and Extraordinary Shareholders’ Meeting were approved.
Key items included approval of 2025 financial statements, a EUR 0.054 dividend per share, board and auditor appointments, a new treasury share authorization, and by-law amendments.
Stevanato Group (NYSE: STVN) reported Q1 FY2026 revenue of €273.6M, up 7% (10% constant currency), with 47% of sales from high-value solutions. Adjusted EBITDA was €65.5M (margin 23.9%); diluted EPS €0.10 and adjusted diluted EPS €0.11. Fiscal 2026 guidance is maintained.